Surrozen, Inc.

NasdaqCM SRZN

Surrozen, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -188.26%

Surrozen, Inc. EBIT Margin is -188.26% for the Trailing 12 Months (TTM) ending September 30, 2024, a 35.38% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Surrozen, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -291.33%.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

NasdaqCM: SRZN

Surrozen, Inc.

CEO	Mr. Craig C. Parker M.B.A.
IPO Date	Jan. 11, 2021
Location	United States
Headquarters	171 Oyster Point Boulevard
Employees	42
Sector	Healthcare
Industries Biotechnology Pharmaceuticals

Description

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Key trends

Past 5 years